NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ALPN Stock Alerts $64.63 +0.06 (+0.09%) (As of 03:34 PM ET) Add Compare Share Share Today's Range$64.54▼$64.6550-Day Range$29.88▼$64.5852-Week Range$6.71▼$64.70Volume1.57 million shsAverage Volume1.92 million shsMarket Capitalization$4.24 billionP/E RatioN/ADividend YieldN/APrice Target$50.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alpine Immune Sciences alerts: Email Address Alpine Immune Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside22.1% Downside$50.33 Price TargetShort InterestHealthy7.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 7 Articles This WeekInsider TradingSelling Shares$5,192 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.74) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector679th out of 907 stocksPharmaceutical Preparations Industry311th out of 422 stocks 2.1 Analyst's Opinion Consensus RatingAlpine Immune Sciences has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAlpine Immune Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.23% of the outstanding shares of Alpine Immune Sciences have been sold short.Short Interest Ratio / Days to CoverAlpine Immune Sciences has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpine Immune Sciences has recently decreased by 10.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpine Immune Sciences does not currently pay a dividend.Dividend GrowthAlpine Immune Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALPN. Previous Next 2.7 News and Social Media Coverage News SentimentAlpine Immune Sciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Alpine Immune Sciences this week, compared to 3 articles on an average week.Search InterestOnly 30 people have searched for ALPN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpine Immune Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,192.00 in company stock.Percentage Held by Insiders42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.74) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpine Immune Sciences is -100.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpine Immune Sciences is -100.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpine Immune Sciences has a P/B Ratio of 11.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Alpine Immune Sciences Stock (NASDAQ:ALPN)Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ALPN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALPN Stock News HeadlinesApril 23, 2024 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN)April 21, 2024 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Sees Unusually-High Trading VolumeApril 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 21, 2024 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Given Average Recommendation of "Hold" by AnalystsApril 18, 2024 | msn.comTD Cowen Downgrades Alpine Immune Sciences (ALPN)April 17, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPNApril 17, 2024 | msn.comAlpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24April 17, 2024 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Receives Hold Rating from TD CowenApril 25, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 17, 2024 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest UpdateApril 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 15, 2024 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) to Post Q1 2024 Earnings of ($0.45) Per Share, Wedbush ForecastsApril 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. BuyoutApril 12, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 11, 2024 | finance.yahoo.comThese Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and MoreApril 11, 2024 | seekingalpha.comVertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'April 11, 2024 | barrons.comVertex Pharmaceuticals to Buy Alpine Immune in $4.9B DealApril 11, 2024 | investors.comAlpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy ItApril 11, 2024 | investorplace.comThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% TodayApril 11, 2024 | proactiveinvestors.comAlpine Immune Sciences soars on $4.9bn Vertex takeoverApril 10, 2024 | investopedia.comVertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to WatchApril 10, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with VertexApril 10, 2024 | businesswire.comALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to ShareholdersApril 10, 2024 | investors.comVertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealApril 10, 2024 | reuters.comVertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 blnApril 10, 2024 | bloomberg.comAlpine Immune Is Weighing Options After Takeover InterestSee More Headlines Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALPN CUSIPN/A CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees142Year FoundedN/APrice Target and Rating Average Stock Price Target$50.33 High Stock Price Target$65.00 Low Stock Price Target$18.00 Potential Upside/Downside-22.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,180,000.00 Net Margins-54.66% Pretax Margin-54.49% Return on Equity-15.54% Return on Assets-11.34% Debt Debt-to-Equity RatioN/A Current Ratio7.86 Quick Ratio7.86 Sales & Book Value Annual Sales$58.88 million Price / Sales71.96 Cash FlowN/A Price / Cash FlowN/A Book Value$5.64 per share Price / Book11.46Miscellaneous Outstanding Shares65,550,000Free Float37,820,000Market Cap$4.24 billion OptionableOptionable Beta1.14 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Mitchell H. Gold M.D. (Age 56)Executive Chairman & CEO Comp: $778.2kDr. Stanford Peng M.D. (Age 53)Ph.D., President and Head of Research & Development Comp: $751.2kMr. Paul Rickey (Age 45)Senior VP, CFO, Treasurer & Secretary Comp: $577.1kMs. M. Christina Yi (Age 47)Chief Technology Officer Temre JohnsonHead of IR & Corporate CommunicationsDr. Remy Durand Ph.D. (Age 39)Chief Business Officer Dr. Wolfgang Dummer M.D. (Age 58)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsPerrigoNYSE:PRGONuvalentNASDAQ:NUVLMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSBridgeBio PharmaNASDAQ:BBIOView All CompetitorsInsiders & InstitutionsRaymond James Financial Services Advisors Inc.Bought 76,508 shares on 4/23/2024Ownership: 0.117%Vivo Capital LLCSold 298,770 shares on 4/22/2024Ownership: 0.794%Mesirow Financial Investment Management Inc.Bought 10,058 shares on 4/19/2024Ownership: 0.015%Allspring Global Investments Holdings LLCBought 4,926 shares on 4/18/2024Ownership: 0.010%Banque Cantonale VaudoiseBought 20,129 shares on 4/10/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions ALPN Stock Analysis - Frequently Asked Questions Should I buy or sell Alpine Immune Sciences stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares. View ALPN analyst ratings or view top-rated stocks. What is Alpine Immune Sciences' stock price target for 2024? 11 equities research analysts have issued 1 year target prices for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $65.00. On average, they anticipate the company's stock price to reach $50.33 in the next year. This suggests that the stock has a possible downside of 22.1%. View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts. How have ALPN shares performed in 2024? Alpine Immune Sciences' stock was trading at $19.06 at the start of the year. Since then, ALPN stock has increased by 239.0% and is now trading at $64.62. View the best growth stocks for 2024 here. Are investors shorting Alpine Immune Sciences? Alpine Immune Sciences saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 4,740,000 shares, a drop of 10.2% from the March 31st total of 5,280,000 shares. Based on an average daily trading volume, of 2,220,000 shares, the short-interest ratio is presently 2.1 days. View Alpine Immune Sciences' Short Interest. When is Alpine Immune Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALPN earnings forecast. How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings results on Monday, March, 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.47. The biotechnology company earned $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%. What ETFs hold Alpine Immune Sciences' stock? ETFs with the largest weight of Alpine Immune Sciences (NASDAQ:ALPN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Small Cap Growth AlphaDEX Fund (FYC) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN). Who are Alpine Immune Sciences' major shareholders? Alpine Immune Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (0.79%), Raymond James Financial Services Advisors Inc. (0.12%), Banque Cantonale Vaudoise (0.03%), Mesirow Financial Investment Management Inc. (0.02%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway. View institutional ownership trends. How do I buy shares of Alpine Immune Sciences? Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALPN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
